Healthy
Conditions
Brief summary
This study is a Phase I, randomized, open-label, cross-over study with three single-dose treatments to compare the bioavailability of an oral tablet relative to an oral capsule of GLPG1690 after single dose intake in healthy male subjects and to evaluate the effect of food on the bioavailability of the oral tablet.
Interventions
DRUGGLPG1690
Oral administration of GLPG1690 in three different treatment conditions (treatment A through C)
Sponsors
Galapagos NV
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
1. Male between 18-50 years of age, inclusive 2. Body mass index (BMI) between 18-30 kg/m2, inclusive, with a weight of at least 50 kg. 3. Judged by the investigator to be in good health based upon the results of a medical history, physical examination, vital signs, 12-lead ECG, and laboratory findings. 4. Discontinuation of all medications except occasional paracetamol at least 2 weeks or 5 half-lives prior to the first study drug administration 5. Non-smokers and not using any nicotine-containing products. 6. Negative urine drug screen and alcohol breath test. 7. Current sexually active male agrees to use adequate contraception/preventive exposure measures from the time of first dose of study drug, during the study and until 12 weeks after the last study drug dose. 8. Subjects should be willing to consume the non-vegetarian high-fat and high-calorie breakfast. 9. Able and willing to sign the ICF
Exclusion criteria
1. Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug 2. Positive serology for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV) or any history of hepatitis from any cause with the exception of hepatitis A. 3. History of or a current immunosuppressive condition. 4. Presence of abnormal liver function. Diagnosis of disease of Gilbert is accepted. Retesting is allowed. 5. Renal function with an estimated creatinine clearance \<80 ml/min based on the Cockcroft-Gault formula. Retesting is allowed. 6. Presence of any condition known to interfere with absorption, distribution, metabolism or excretion of drugs. 7. History of malignancy within the past 5 years 8. Clinically relevant abnormalities detected on ECG regarding either rhythm or conduction (e.g., QTcF \>450 ms, or a known long QT syndrome). 9. Clinically relevant abnormalities detected on vital signs. 10. Dietary requirements precluding participation in the study 11. Significant blood loss (including blood donation \[≥450 mL\]), or transfusion of any blood product within 8 weeks prior to the signing of ICF. 12. Active drug or alcohol abuse within 2 years prior to the initial study drug administration. 13. Consumption of large quantities of caffeinated coffee or tea (\>6 cups/day), or equivalent. 14. Concurrent participation or participation in a drug or drug/device investigational research study. 15. Subjects who participated in a previous study with the same compound (GLPG1690). 16. Investigator or any sub-investigator, or other staff or relative. 17. Any condition or circumstances that in the opinion of the investigator may make a subject unlikely or unable to complete the study or comply with study procedures and requirements.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of the maximum observed plasma concentration of GLPG1690 after single oral doses | predose at day 1 and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 48 hours post dosing | Determine the bioavailability of GLPG1690 by assessing PK parameters |
| Assessment of the time to reach the maximum observed plasma concentration of GLPG1690 after single oral doses | predose at day 1 and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 48 hours post dosing | Determine the bioavialability of GLPG1690 by assessing PK parameters |
| Assessment of the time of the last quantifiable plasma concentration of GLPG1690 after single oral doses | predose at day 1 and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 and 48 hours post dosing | Determine the bioavialability of GLPG1690 by assessing PK parameters |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The number of subjects with abnormal physical examination | Throughout the study from screening until the follow up visit (day 7 of dosing period 3) | To assess safety and tolerability of GLPG1690 |
| The number of subjects with adverse events | Throughout the study from screening until the follow up visit (day 7 of dosing period 3) | To assess safety and tolerability of GLPG1690 |
| The number of subjects with abnormal laboratory analysis | Throughout the study from screening until the follow up visit (day 7 of dosing period 3) | To assess safety and tolerability of GLPG1690 |
| The number of subjects with abnormal vital signs | Throughout the study from screening until the follow up visit (day 7 of dosing period 3) | To assess safety and tolerability of GLPG1690 |
| The number of subjects with abnormal ECG | Throughout the study from screening until the follow up visit (day 7 of dosing period 3) | To assess safety and tolerability of GLPG1690 |
Countries
Belgium
Outcome results
None listed